The Rogosin Institute was established in New York City in 1983 as an independent, not-for-profit institution for research, treatment and prevention of kidney disease.  Rogosin’s history can be traced back to 1955 when the first Cardiorenal Laboratory at Bellevue Hospital in New York City was created and became the predecessor for ensuing kidney programs.

 Rogosin is affiliated with NewYork-Presbyterian Hospital, Weill Cornell Medical College and is a member of the NewYork Presbyterian Regional Hospital Network.  Most all of our physicians have appointments in NewYork-Presbyterian Hospital and Weill Cornell Medical College.

 First Hemodialysis

In 1957, Albert L. Rubin (founder of Rogosin), and his team performed the first hemodialysis in the metropolitan area as a treatment for kidney failure.  In 1962, the “unit” became known as the Renal Laboratory as moved to what was The New York Hospital, now known as NewYork-Presbyterian Hospital.  There it expanded to the Rogosin Renal Laboratories, named in honor of Israel Rogosin (1886-1971), an American textile industrialist and philanthropist who was a generous benefactor to New York Hospital.

 First Kidney Transplant

The first kidney transplant in the metropolitan area was performed by the Rogosin renal group in 1963.  Following continued growth of the kidney disease program, what was then The New York Hospital/Cornell Medical Center was designated by the Department of Health of the State of New York as a Regional Kidney Disease Center in 1968 and the laboratories then became formally known as the Rogosin Kidney Center.  In 1983, with a growing expansion of research and treatment activities, The Rogosin Institute was founded as an independent, not-for-profit entity, with Rogosin Kidney Center as one of its components.

In 1985, The Rogosin Institute established the Immunogenetics and Transplantation Laboratory (IGT), which was one of the first and remains one of the largest solid-organ immunogenetics laboratories in the Northeast. Today, the laboratory continues to provide the highest quality testing to determine compatibility between a patient and a donor and its services are used by many transplant centers.

 Expansion

 During the 1990s continued growth and expansion occurred.  The Rogosin Institute had opened additional clinical facilities in Queens and Brooklyn and research facilities for diabetes and cancer research in Xenia, Ohio.  Clinical research activities in NYC expanded with research in kidney disease and cardiovascular disease and the clinical research program for cancer began investigational treatment for patients.

 Expansion also included initiation of the home nocturnal hemodialysis training and treatment program in 2001, and in 2002 the launch of the Susan R. Knafel Polycystic Kidney Disease Center as of the only treatment centers for polycystic kidney disease in the Northeast area.

 During the next decade dialysis facilities were added in Auburndale, Queens and three additional centers in Brooklyn.

 In 2015, the new Maurice R. & Corinne P. Greenberg Center for Integrative Health at The Rogosin Institute was opened on West 54th Street in New York City.  This center encompasses Rogosin’s Westside Dialysis Center and the Center for Health Action and Policy (CHAP).  CHAP is a center for local and national community and professional healthcare education and community outreach training, along with healthcare data analysis and policy involvement on a range of the most important contemporary health issues.

 Rogosin now provides dialysis treatments for over 1500 patients and care for over 20,000 patients with chronic kidney disease

 In-Patient Care Facilities

Within NewYork-Presbyterian /Weill Cornell, inpatient facilities include The Rogosin Institute Wing for patients requiring hospitalization for kidney disease related problems and kidney transplantation; and The Rogosin Institute Dialysis and Apheresis Center for patients undergoing intensive care hemodialysis.  The Rogosin Institute also has access to NewYork-Presbyterian Hospital/Weill Cornell’s Clinical Research Center (CRC) and The Rockefeller University’s Clinical Research Center for inpatient studies.